Dander et al. [65] identified and validated interleukin 2 receptor alpha (IL-2Rα), tumor necrosis factor receptor (TNFR) I, and elafin as reliable to predict the response of patients with GVHD to MSCs. The gene discussed is TNFRSF1A; the disease is graft versus host disease.